Yusri Elsayed

3.9k total citations · 2 hit papers
51 papers, 2.4k citations indexed

About

Yusri Elsayed is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Yusri Elsayed has authored 51 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 22 papers in Hematology and 19 papers in Molecular Biology. Recurrent topics in Yusri Elsayed's work include Multiple Myeloma Research and Treatments (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Peptidase Inhibition and Analysis (7 papers). Yusri Elsayed is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Peptidase Inhibition and Analysis (7 papers). Yusri Elsayed collaborates with scholars based in United States, France and Belgium. Yusri Elsayed's co-authors include Edward A. Sausville, Manish Monga, Margaret von Mehren, Johann S. de Bono, Claudia Lebedinsky, Jean‐Yves Blay, Brian L. Samuels, Sant P. Chawla, Axel Le Cesne and Miguel Izquierdo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Yusri Elsayed

50 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

2009 397 citations George D. Demetri, Jean‐Yves Blay et al. Journal of Clinical Oncology profile →
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

2012 336 citations Kenneth J. Pienta, Jean-Pascal Machiels et al. Investigational New Drugs profile →

Peers

Countries citing papers authored by Yusri Elsayed

Since Specialization

Citations

This map shows the geographic impact of Yusri Elsayed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusri Elsayed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusri Elsayed more than expected).

Fields of papers citing papers by Yusri Elsayed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusri Elsayed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusri Elsayed. The network helps show where Yusri Elsayed may publish in the future.

Co-authorship network of co-authors of Yusri Elsayed

This figure shows the co-authorship network connecting the top 25 collaborators of Yusri Elsayed. A scholar is included among the top collaborators of Yusri Elsayed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusri Elsayed. Yusri Elsayed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models 2025 ·Blood ·Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro, Jianhong Yao, Melissa Smith, (unknown), James Testa, (unknown), Scott R. Brodeur, (unknown), Kathryn Packman, Sanjaya Singh, Ricardo M. Attar, Yusri Elsayed, Ulrike Philippar	3
2	Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma 2023 ·Blood ·(unknown), Danlin Yang, Jianhong Yao, Melissa Smith, Leopoldo Luistro, (unknown), James Testa, Kathryn Packman, Scott R. Brodeur, Ricardo M. Attar, Yusri Elsayed, Ulrike Philippar	19
3	Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma 2022 ·Blood Advances ·Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, (unknown), Xin Miao, Yang Chen, Tara Stephenson, Arnob Banerjee, Brandi Hilder, Jeffery S. Russell, Jeffrey R. Infante, Yusri Elsayed, Jennifer Smit, Jenna D. Goldberg	30
4	Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma 2022 ·Targeted Oncology ·Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong‐Yuan Yang, Brandi Hilder, Qun Jiao, (unknown), Homer Adams, Yu‐Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed	10
5	A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms 2014 ·Cancer Chemotherapy and Pharmacology ·William D. Figg, Manish Monga, Donna Headlee, (unknown), Cindy H. Chau, Cody J. Peer, (unknown), Yusri Elsayed, Anthony J. Murgo, Giovanni Melillo, Qin Ryan, (unknown), Adrian M. Senderowicz, Melinda G. Hollingshead, Susan G. Arbuck, Edward A. Sausville	15
6	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, (unknown), Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji	97
7	Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial 2012 ·Journal of Hematology & Oncology ·Pier Luigi Zinzani, Nuriet K. Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie‐Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri Elsayed, Bertrand Coiffier	17
8	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer breakdown → 2012 ·Investigational New Drugs ·Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers, B. Yа. Alekseev, М. I. Shkolnik, Simon J. Crabb, Susan Li, Shobha Seetharam, Thomas A. Puchalski, Chris H. Takimoto, Yusri Elsayed, Fitzroy W. Dawkins, Johann S. de Bono	336
9	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects 2011 ·QJM ·Simon W Dubrey, Donna Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Jean Paul Fermand, Robert Vescio, Joan Bladé, Leonard T. Heffner, Hani Hassoun, (unknown), Christopher Enny, Priya Ramaswami, Yusri Elsayed, Helgi van de Velde, (unknown), Andrew Cakana, Raymond L. Comenzo, (unknown)	37
10	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial 2011 ·The Lancet Oncology ·Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiřı́ Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie‐Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri Elsayed, Pier Luigi Zinzani	81
11	Overall Survival: A Gold Standard in Search of a Surrogate 2009 ·The Cancer Journal ·Sen Hong Zhuang, Liang Xiu, Yusri Elsayed	40
12	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study 2009 ·Blood ·Donna Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Jean-Paul Fermand, Robert Vescio, Xiangyang Liu, Yusri Elsayed, Andrew Cakana, Raymond L. Comenzo, (unknown)	112
13	Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors 2008 ·Cancer Chemotherapy and Pharmacology ·Wells A. Messersmith, Antonio Jimeno, David S. Ettinger, Dan Laheru, Julie R. Brahmer, (unknown), Yasmin Khan, Ross C. Donehower, Yusri Elsayed, Peter Zannikos, Manuel Hidalgo	28
14	7500 ORAL Impact of independent review on efficacy outcomes in a randomised multicenter trial of trabectedin given by two dosing regimens in patients (pts) with progressing leiomyosarcomas or liposarcomas (L-sarcomas) 2007 ·European Journal of Cancer Supplements ·George D. Demetri, Scott M. Schuetze, Axel Le Cesne, (unknown), Paolo G. Casali, (unknown), (unknown), Yusri Elsayed, Miguel Izquierdo, Jean‐Yves Blay	2
15	Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL) 2007 ·Journal of Clinical Oncology ·DE Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Jean Paul Fermand, Robert Vescio, (unknown), Yusri Elsayed, Raymond L. Comenzo	6
16	Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma 2005 ·International Journal of Radiation OncologyBiologyPhysics ·Carter Van Waes, Angela A. Chang, Peter F. Lebowitz, Colleen Druzgal, Zhong Chen, Yusri Elsayed, John B. Sunwoo, Susan F. Rudy, John C. Morris, James B. Mitchell, Kevin Camphausen, David Gius, Julian Adams, Edward A. Sausville, Barbara A. Conley	93
17	A first in human trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. 2004 ·Cancer Research ·(unknown), Donna Headlee, Yusri Elsayed, (unknown), Alex Sparreboom, (unknown), Jane B. Trepel, Anthony J. Murgo, James A. Zwiebel, E. A. Sausville	2
18	Effects of Recombinant Human Tissue Factor Pathway Inhibitor on Thrombus Formation and ItsIn VivoDistribution in a Rat DIC Model 1996 ·American Journal of Clinical Pathology ·Yusri Elsayed, Kazunori Nakagawa, (unknown), Keiichi Enjyoji, (unknown), Katsuo Sueishi	30
19	Expression of Tissue Factor and lnterleukin-1β in a Novel Rabbit Model of Disseminated Intravascular Coagulation Induced by Carrageenan and Lipopolysaccharide 1995 ·Pathobiology ·Yusri Elsayed, Kazunori Nakagawa, Kojiro Ichikawa, Susumu Ohkawara, Katsuo Sueishi	18
20	Procoagulant Properties of Atherosclerotic Aortas^a 1994 ·Annals of the New York Academy of Sciences ·Katsuo Sueishi, Kojiro Ichikawa, Kazunori Nakagawa, Kazuhiko Kato, Yusri Elsayed, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact